Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.
TipRanks on MSN

Milestone’s PSVT nasal spray MAA accepted by EMA

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...
Investing

European regulators accept etripamil nasal spray application for PSVT

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Tuesday that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal ...
Yahoo Finance

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
Monthly Prescribing Reference

Cardamyst Approved for Self-Treatment of PSVT Episodes

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...
Seeking Alpha

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Greetings. Welcome to Milestone Pharmaceuticals CARDAMYST FDA Approval Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to Michael Wood ...
Business Insider

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Investing

Milestone stock soars after FDA approves first self-administered PSVT spray

Investing.com -- Milestone Pharmaceuticals (NASDAQ:MIST) stock surged 35% after the company received FDA approval for CARDAMYST, the first self-administered nasal spray for adults with paroxysmal ...
Nasdaq

FDA Approves Milestone Pharma' CARDAMYST, First Self-Administered Treatment For PSVT

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription ...